Latest Regulatory Approvals News

Great Divide Mining has completed its acquisition of the remaining Challenger Mines shares, gaining full ownership and setting a revised, sole-funded development plan targeting initial cashflow by the end of Q3 FY26.

Hot Chili Limited has launched a A$40 million private placement to accelerate development of its Fuego copper project in Costa Rica, issuing shares at a discount to recent prices. The capital raise aims to boost exploration and feasibility studies while enhancing liquidity on the TSX Venture Exchange.

Bellavista Resources has announced a transformative acquisition of a 70% interest in the Pickle Crow Gold Project in Ontario, Canada, alongside a A$25 million equity raise to fund exploration and development.

Bellavista Resources Ltd has agreed to acquire a majority stake in the high-grade Pickle Crow Gold Project in Ontario, Canada, boasting a 2.8 million ounce inferred resource at 7.2g/t gold. The company is also raising up to A$25 million to fund aggressive exploration and development.

Bellavista Resources Ltd has agreed to acquire up to 80% of the Pickle Crow Gold Project in Ontario, Canada, adding a 2.8 million ounce inferred gold resource at 7.2g/t to its portfolio. The company is raising A$25 million to fund aggressive exploration and development activities.

Mamba Exploration Limited has inked a deal to acquire a majority interest in the underexplored Meeka East Gold Project in Western Australia’s prolific Murchison Goldfield, backed by a $2 million capital raise to fund early-stage exploration.

FireFly Metals has agreed to sell its Ontario gold assets, including a 70% stake in the Pickle Crow Project, to Bellavista Resources for up to A$86.1 million in scrip. FireFly shareholders will receive Bellavista shares, maintaining exposure to the assets while FireFly focuses on its copper-gold ambitions.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

Neurotech International has secured ethics approval to launch its Beyond Harmony Phase 3 clinical trial of NTI164 for autism spectrum disorder, marking a key step toward regulatory submissions in Australia and the US.

CurveBeam AI has received the first A$4 million tranche of a planned A$10 million strategic investment from a leading Chinese orthopaedic device company, marking a significant step in its expansion into the Chinese market.